My Profile

Search abstracts

Lewis Sheiner

Stockholm, Sweden

Montreux, Switzerland

Budapest, Hungary

Lisboa, Portugal

Hersonissos, Crete, Greece

Alicante, Spain

Glasgow, Scotland

Venice, Italy

Athens, Greece

Berlin, Germany

St. Petersburg, Russia

Marseille, France

KÝbenhavn, Denmark

Brugge/Bruges, Belgium

Pamplona, Spain

Uppsala, Sweden

Verona, Italy

Paris, France

Basel, Switzerland

Salamanca, Spain

Saintes, France

Wuppertal, Germany

Glasgow, Scotland

Sandwich, UK

Frankfurt, Germany

Greenford, UK

Paris, France

Basel, Switzerland

Printable version

PAGE. Abstracts of the Annual Meeting of the Population Approach Group in Europe.
ISSN 1871-6032

PAGE 27 (2018) Abstr 8451 []

Poster: Drug/Disease modelling - Other topics

II-59 Fredrik Jonsson Exposure-Response Modeling of Emicizumab for the Prophylaxis of Bleeding in Hemophilia A Patients

F. Jonsson (1), F. Mercier (2), N.H. Prins (1), C. Schmitt (2), S. Retout (2)

(1) qPharmetra, Andover MA, (2) Roche Pharma Research and Early Development, Pharmaceutical Sciences, Clinical Pharmacology, Roche Innovation Center, Basel, Switzerland

Objectives: Emicizumab has recently been approved in the US for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A with factor VIII (FVIII) inhibitors. Emicizumab is a recombinant, humanized, bispecific, immunoglobulin G4 (IgG4) monoclonal antibody that binds with moderate affinity to activated factor IX (FIXa) and factor X (FX) and has co-factor activity that substitutes for activated FVIII. Therefore it is capable of promoting the activation of FX by FIXa. Emicizumab activates downstream hemostasis at the site of bleeding in hemophilia A patients who have hypofunctional levels or entirely lack FVIII [1]. Up to 30% of patients with hemophilia A develop neutralizing alloantibodies against FVIII (inhibitors). In patients with hemophilia A, hemostasis can be restored irrespective of the presence of FVIII inhibitors, as emicizumab shares no sequence homology with FVIII.

Our main objective is to assess and quantify the relationship between exposure to emicizumab and reduction in the annualized bleeding rate (ABR) among hemophilia A patients. In addition, we want to perform simulations exploring the effect on bleeding count at different doses in order to support the intended dose regimen

Methods: Bleeding event data were pooled from 301 hemophilia A patients participating in four clinical studies [2-6], including one non-intervention study where no emicizumab was given [6]. Emicizumab exposure was predicted using a previously developed population pharmacokinetic model. Bleeding event data were transformed into daily bleed frequencies and analyzed as count data [7,8] using a PKPD model implemented in NONMEM version 7.3 (ICON Development Solutions), with a small run-in METHOD=SAEM to obtain a solid starting position for the subsequent main estimation run using MCMC Bayesian. Models with Poisson, generalized Poisson, and negative binomial (NB) distributions were fit to the data and assessed. Several forms of exposure-response relationships were tested: linear, all or nothing, power and Emax models. After selection of an appropriate structural model, the following covariates were tested on all exposure-response model parameters: adjunctive hemophilic treatment (episodic/prophylactic), FVIII inhibitor status (yes/no), FIX and FX concentration at baseline, baseline ABR, as well as demographic covariates. A stepwise procedure was implemented to screen the covariates. Candidate covariate models were then compared by Objective Function Value (OFV), Akaike Information Criterion (AIC), and precision of parameter estimates. The final model was subjected to a Visual Predictive Check (VPC) and subsequently used to simulate the progression of ABR over time. The simulation results were summarized in the form of change from baseline and fraction of bleed free patients.

Results: The generalized Poisson distribution (characterized by two parameters λ and ω) provided the best description of the data, although low differences were seen with the NB distribution. The best fit model included an Emax relationship for the effect of emicizumab concentrations on the parameter λ, which described the mean daily bleed frequency. The bleed frequency was estimated to be mildly over-dispersed between patients, as indicated by the dispersion factor (ω) estimate. The mean values (%Relative Standard Error) for λ, ω, maximum treatment effect, and EC50 were 0.0356 (8.4%), 0.0244 (19%), 0.979 (1.1%), 2.72 ug/mL (20%), respectively. The estimated Emax corresponds to 97.9% reduction of bleed frequency. The inter-individual exponential variability of λ was 108%. No significant covariates were found. The VPC showed good agreement with the data.

The model was then used to simulate bleeding count over 1 year under different treatment regimens for a large Phase 3 trial with 300 patients. The observed daily mean concentrations at the intended therapeutic dose of 1.5 mg/kg were around 50 µg/ml. The simulated mean bleeding count at 50 µg/ml was 2, which corresponds to a 91% reduction compared to no emicizumab prophylaxis.  

Conclusions: Occurrence of bleeding events  was described well by a generalized Poisson model, and showed important reduction of the endpoint with increasing emicizumab concentrations following an Emax relationship. The suggested therapeutic dose of 1.5 mg/kg is predicted to provide a 91% mean reduction of ABR compared to no emicizumab prophylaxis, which is close to the estimated maximum effect.

[1] Sampei Z, Igawa T, Soeda T, et al. Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity. PLoS ONE 2013;8:e57479.
[2] Shima M, Hanabusa H, Taki M, Matsushita T, Sato T, Fukutake K, Fukazawa N, Yoneyama K, Yoshida H, Nogami K. Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A. N Engl J Med. 2016 May 26;374(21):2044-53. doi: 10.1056/NEJMoa1511769
[3] Shima M, Hanabusa H, Taki M, Matsushita T, Sato T, Fukutake K, Kasai R, Yoneyama K, Yoshida H, Nogami K. Long-term safety and efficacy of emicizumab in a phase 1/2 study in patients with hemophilia A with or without inhibitors. Blood Adv. 2017 Sep 27;1(22):1891-1899. doi: 10.1182/bloodadvances.2017006684.
[4] Oldenburg J, Mahlangu JN, Kim B, Schmitt C, Callaghan MU, Young G, Santagostino E, Kruse-Jarres R, Negrier C, Kessler C, Valente N, Asikanius E, Levy GG, Windyga J, Shima M. Emicizumab Prophylaxis in Hemophilia A with Inhibitors. N Engl J Med. 2017 Aug 31;377(9):809-818
[5] Young G, Sidonic RF, Liesner R, Oldenburg J, Chang T, Uguen M, Dhalluin C, Schmitt C, Levy GG, Shima M, Mahlangu J. HAVEN 2 Updated Analysis: Multicenter, Open-Label, Phase 3 Study to Evaluate Efficacy, Safety and Pharmacokinetics of Subcutaneous Administration of Emicizumab Prophylaxis in Pediatric Patients with Hemophilia A with Inhibitors. Oral presentation, ASH Annual Meeting, Atlanta, GA, 9-12 December 2017
[6] Mahlangu J, Oldenburg J, Callaghan M, Shima M, Santagostino E, Moore M, Garcia C, Yang R, Lehle M, Machiara H, Asikanius E, Levy G, Kruse-Jarres R. Bleeding Events and Safety Outcomes in Persons with Hemophilia A (PwHA) with Inhibitors: The First Large, Prospective, Multicenter, Non-interventional Study (NIS) from a Real-World Setting.  Poster presentation, International Society on Thrombosis and Haemostasis Congress, Berlin, Germany, 8–13 July 2017
[7] Plan EL. Modeling and simulation of count data. CPT: Pharmacometrics System Pharmacology, 3:1-12, August 2014.
[8] Prins NH, Dykstra KD, Darekar A, and van der Graaf, PH. Use of a Generalized Poisson model to describe micturition frequency in patients with overactive bladder disease. Poster presentation, PAGE meeting, Athens, 2011.